(Q38073520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Oncolytic virus therapy for cancer: the first wave of translational clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Robert A Kratzke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

10 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

355-364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

Clinical development directions in oncolytic viral therapy

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic virotherapy reaches adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Gene therapy: trials and tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Targeted gene delivery by tropism-modified adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Regression of Hodgkin's disease after measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

7 January 2021

Measles and leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Possible effect of measles on leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Hodgkin's disease: remissions after measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Nectin 4 is the epithelial cell receptor for measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Adherens junction protein nectin-4 is the epithelial receptor for measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Nectin-4 is a new histological and serological tumor associated marker for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Engineered measles virus as a novel oncolytic therapy against prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Measles virus causes immunogenic cell death in human melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.12.010

10.1016/J.TRSL.2012.12.010

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23313629%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference